These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8968528)

  • 1. An investigation of the dose proportionality of deflazacort pharmacokinetics.
    Rao N; Bhargava VO; Reynolds DL; Eller MG; Weir SJ
    Biopharm Drug Dispos; 1996 Dec; 17(9):753-60. PubMed ID: 8968528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Mistry GC; Luo WL; Liu Q; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman GA; Wagner JA; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):307-13. PubMed ID: 17571284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort.
    Kong R; Ma J; Beers B; Kaushik D; Lin E; Goodwin E; Colacino J; Bibbiani F
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00677. PubMed ID: 33090712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of food on the relative bioavailability of deflazacort.
    Rao N; Eller M; Arumugham T; Weir S
    Eur J Drug Metab Pharmacokinet; 1996; 21(3):241-5. PubMed ID: 8980922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
    Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
    J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers.
    Cullen E; Liao J; Lukacsko P; Niecestro R; Friedhoff L
    Biopharm Drug Dispos; 2004 Sep; 25(6):261-3. PubMed ID: 15334625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers.
    Cho HY; Moon JD; Lee YB
    Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of cloprednol.
    Möllmann H; Hochhaus G; Rohatagi S; Barth J; Derendorf H; Krieg M; Weisser H; Möllmann AC
    Int J Clin Pharmacol Ther; 1996 Jan; 34(1):1-5. PubMed ID: 8688990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cloprednol in healthy volunteers.
    Legler UF
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):173-5. PubMed ID: 3403094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form.
    Tuerck D; Appel-Dingemanse S; Maboudian M; Pommier F; Wang Y; Sedek G
    J Clin Pharmacol; 2007 Jan; 47(1):64-9. PubMed ID: 17192503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of glycyrrhetic acid in human plasma by HPLC-MS method and investigation of its pharmacokinetics.
    Zhao WJ; Wang BJ; Wei CM; Yuan GY; Bu FL; Guo RC
    J Clin Pharm Ther; 2008 Jun; 33(3):289-94. PubMed ID: 18452416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of rizatriptan in healthy elderly subjects.
    Musson DG; Birk KL; Panebianco DL; Gagliano KD; Rogers JD; Goldberg MR
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):447-52. PubMed ID: 11680669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
    Fornasini G; Monti N; Brogin G; Gallina M; Eandi M; Persiani S; Bani M; Della Pepa C; Zara G; Strolin Benedetti M
    Chirality; 1997; 9(3):297-302. PubMed ID: 9176996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.